US EditionPublished • loading... • Updated
Citius Oncology launches Lymphir treatment for rare lymphoma
Summary by NJBIZ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Citius Oncology launches Lymphir treatment for rare lymphoma
Citius Oncology Inc. has commercially launched Lymphir, a treatment for Stage I–III cutaneous T-cell lymphoma, the Cranford-based firm announced Dec. 1. In August 2024, the U.S. Food and Drug Administration approved the medication – denileukin diftitox-cxdl – for adults with the rare form of non-Hodgkin lymphoma. That same month, Citius Pharmaceuticals finalized the merger of its wholly owned oncology subsidiary with New York-based TenX Keane …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
